Posted by Michael Wonder on 01 Mar 2024
Intercept announces FDA acceptance of supplemental new drug application for Ocaliva (obeticholic acid) for the treatment of PBC
29 February 2024 - FDA has assigned a PDUFA target action date of 15 October 2024.
Intercept Pharmaceuticals today announced that the US FDA has accepted its supplemental new drug application for Ocaliva for the treatment of individuals with primary biliary cholangitis.
